Tag

Your search for Interferon-free treatment returned 29 results.


6-week Hepatitis C DAA drug regimen is effective

A simple 6-week course of three direct-acting antiviral drugs appears to be effective and well tolerated in patients with chronic HCV genotype 1 infection without cirrhosis Simple hepatitis C treatment regimens with a short duration, low pill burdens, and few adverse effects could improve patient adherence, which is vital considering that the ultimate goal is to ...

Read More


Grazoprevir + elbasvir no ribavirin effective: HCV

Grazoprevir plus elbasvir without ribavirin is effective and well tolerated in previously untreated HCV patients with no cirrhosis, with and without HIV co-infection The combination of grazoprevir plus elbasvir has the potential to provide an all-oral, highly efficacious, simple, and well tolerated regimen for the treatment of hepatitis C virus (HCV) genotype 1 ...

Read More


Grazoprevir + elbasvir for difficult to cure HCV

Grazoprevir plus elbasvir without ribavirin is effective in HCV genotype 1-infected populations that are difficult to cure with HCV therapy (patients with well compensated cirrhosis and null responder patients with or without well compensated cirrhosis) There is a high medical need for an interferon-free, all-oral, short-duration hepatitis C (HCV) therapy that is ...

Read More


Short-duration, IFN- RBV-free regimen for HCV 3

A short-duration, interferon- and ribavirin-free regimen of daclatasvir plus sofosbuvir is efficacious and tolerable in patients with chronic hepatitis C genotype 3 infection Patients with chronic hepatitis C genotype 3 (HCV 3) infection have a higher risk of progression to cirrhosis, as well as development of steatosis or hepatocellular carcinoma, than those ...

Read More


Outcomes improved during Hepatitis C treatment

An interferon-free and ribavirin-free anti-HCV regimen is shown to improve patient-reported outcomes during treatment Chronic HCV infection causes a tremendous clinical and economic burden to society. Patient-reported outcomes (PROs) such as health-related quality of life (HRQL) and work productivity are negatively impacted by HCV-related liver disease (cirrhosis, ...

Read More


Hepatitis C: topical and comprehensive seminar

The Lancet has published a topical and comprehensive seminar on hepatitis C The March 2015 issue of the Lancet contains an authoritative seminar on hepatitis C (Webster DP, et al. Lancet. 2015;385:1124-1135). The Lancet is one of the world's leading medical journals; an independent and authoritative voice in global medicine. Dr. Daniel Webster and colleagues' ...

Read More


Perfectovir is a realizable goal: an HCV revolution

The development of “Perfectovir” is a realizable goal: a revolution in the treatment of Hepatitis C has begun! The key attributes of an optimal HCV treatment regimen were recently outlined by Gregory Dore and Jordan Feld in an invited review article published in the journal Clinical Infectious Diseases (Dore GJ, Feld JJ. Clin Infect Dis. 2015 Mar 11. pii: ...

Read More


Two DAA regimen effective in difficult to treat HCV

Regimen of two direct-acting oral antivirals appears effective in patients with difficult to treat HCV subgenotypes 1a and 2b Therapies for HCV genotype 1, 2, and 3 infection have traditionally been peginterferon (pegIFN)-based. PegIFN is associated with adverse events including influenza-like symptoms and depression. Many patients decline PegIFN therapy, and a ...

Read More


A Truly Historic Era in Hepatitis C Therapy

We are entering a truly historic era in hepatitis C therapy. The recent introduction of oral, well-tolerated, limited-duration therapies with over 95% cure rates makes the once unrealistic aspiration of eradicating hepatitis C infection a realizable goal. However, several major hurdles need to be cleared before this objective can be achieved. Foremost is the identi...

Read More